靶向蛋白生物素化增强结核化疗效果
研究验证细菌生物素蛋白连接酶(BPL)作为结核治疗新靶点:化学抑制剂Bio-AMS可杀死结核分枝杆菌,遗传沉默BPL可在急性和慢性感染小鼠中清除病原体;部分化学失活BPL增强利福平和乙胺丁醇的效力,遗传干扰蛋白生物素化加速利福平清除小鼠肺脾中的结核分枝杆菌。
要点
- BPL化学抑制或遗传沉默均可杀死或清除结核分枝杆菌
- 部分失活BPL增强利福平和乙胺丁醇的效力
- 遗传干扰蛋白生物素化加速利福平清除小鼠体内结核分枝杆菌
核心结论
- BPL是潜在药物靶点,可作为结核新药开发中的替代一线靶点。
研究设计与样本
- 研究使用化学抑制剂Bio-AMS和遗传沉默/干扰手段,在结核分枝杆菌及急性和慢性感染小鼠模型中验证BPL靶点。
主要发现
- Bio-AMS抑制BPL可杀死结核分枝杆菌。
- 遗传沉默BPL在急性和慢性感染小鼠中有效清除病原体。
- 部分化学失活BPL增强利福平和乙胺丁醇的效力。
- 遗传干扰蛋白生物素化加速利福平清除小鼠肺和脾中的结核分枝杆菌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Successful drug treatment for tuberculosis (TB) depends on the unique contributions of its component drugs. Drug resistance poses a threat to the efficacy of individual drugs and the regimens to which they contribute. Biologically and chemically validated targets capable of replacing individual components of current TB chemotherapy are a major unmet need in TB drug development. We demonstrate that chemical inhibition of the bacterial biotin protein ligase (BPL) with the inhibitor Bio-AMS (5'-[N-(d-biotinoyl)sulfamoyl]amino-5'-deoxyadenosine) killed Mycobacterium tuberculosis (Mtb), the bacterial pathogen causing TB. We also show that genetic silencing of BPL eliminated the pathogen efficiently from mice during acute and chronic infection with Mtb Partial chemical inactivation of BPL increased the potency of two first-line drugs, rifampicin and ethambutol, and genetic interference with protein biotinylation accelerated clearance of Mtb from mouse lungs and spleens by rifampicin. These studies validate BPL as a potential drug target that could serve as an alternate frontline target in the development of new drugs against Mtb.
引用
- Tiwari D, Park SW, Essawy MM, et al. Targeting protein biotinylation enhances tuberculosis chemotherapy. Sci Transl Med. 2018. PMID: 29695454. doi:10.1126/scitranslmed.aal1803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。